Publication Details

Publication Categories

Browse C5 Companies

C5 Group
www.C5groupinc.com

Canadian Institute
www.canadianinstitute.com

C5 (UK)
www.C5-online.com
ACI : Conference-Papers : 2004 : Pharma and Biotech In-Licensing, Co-Development, and Co-Promotion Agreements

Structuring, Negotiating and Managing Win/Win

Pharma and Biotech In-Licensing, Co-Development, and Co-Promotion Agreements

Thursday, November 13, 2003

About

Do you have the up-to-the-minute information and skills you need to structure, negotiate and manage successful deals?

In its efforts to fill the pipeline, reduce costs and leverage assets, the pharmaceutical industry is increasingly relying on collaborations - within the industry and with biotech - that include in-licensing, co-development and co-promotion arrangements.

While these arrangements can be highly profitable, they are rife with potential misunderstandings and other minefields. Yet many of the conflicts which end up destroying potentially lucrative relationships can be avoided at the outset - if you know how to negotiate, structure and draft a tight, yet flexible agreement in a timely manner.

With the high stakes - and high hopes - surrounding collaborations, it is imperative that in-house counsel, senior business executives and attorneys advising the pharmaceutical industry have an up-to-the minute and in-depth understanding of the legal and business issues surrounding in-licensing, co-development and co-promotion transactions in today's market.

American Conference Institute's Second Annual, In-Licensing, Co-Development and Co-Promotion Agreements publication will provide you with the tools you need to create sound agreements. This expert faculty of leading pharmaceutical and biotech in-house counsel and executives as well as expert attorneys and investment bankers, will provide valuable insights on:
  • Drivers and other extraneous forces that are pushing these types of collaborations forward in this market
  • How to overcome financing and funding obstacles in this economy
  • Important topics to add to your due diligence check list
  • Avoiding and surviving anti-trust scrutiny
  • How to choose a governance structure that best suits the deal
  • Successful troubleshooting for collaborations with established players, the up-and-coming, and academia
  • Circumventing problems unique to co-promotion collaborations
  • How to make a graceful and uneventful exit
This is by far the most comprehensive publication of the year on in-licensing, co-development and co-promotion.

Contents & Contributors

About

Do you have the up-to-the-minute information and skills you need to structure, negotiate and manage successful deals?

In its efforts to fill the pipeline, reduce costs and leverage assets, the pharmaceutical industry is increasingly relying on collaborations - within the industry and with biotech - that include in-licensing, co-development and co-promotion arrangements.

While these arrangements can be highly profitable, they are rife with potential misunderstandings and other minefields. Yet many of the conflicts which end up destroying potentially lucrative relationships can be avoided at the outset - if you know how to negotiate, structure and draft a tight, yet flexible agreement in a timely manner.

With the high stakes - and high hopes - surrounding collaborations, it is imperative that in-house counsel, senior business executives and attorneys advising the pharmaceutical industry have an up-to-the minute and in-depth understanding of the legal and business issues surrounding in-licensing, co-development and co-promotion transactions in today's market.

American Conference Institute's Second Annual, In-Licensing, Co-Development and Co-Promotion Agreements publication will provide you with the tools you need to create sound agreements. This expert faculty of leading pharmaceutical and biotech in-house counsel and executives as well as expert attorneys and investment bankers, will provide valuable insights on:
  • Drivers and other extraneous forces that are pushing these types of collaborations forward in this market
  • How to overcome financing and funding obstacles in this economy
  • Important topics to add to your due diligence check list
  • Avoiding and surviving anti-trust scrutiny
  • How to choose a governance structure that best suits the deal
  • Successful troubleshooting for collaborations with established players, the up-and-coming, and academia
  • Circumventing problems unique to co-promotion collaborations
  • How to make a graceful and uneventful exit
This is by far the most comprehensive publication of the year on in-licensing, co-development and co-promotion.

Contents & Contributors

THE GOVERNANCE AND MANAGEMENT OF COLLABORATIONS
Deni M. Zodda, Ph.D, Discovery Laboratories, Inc.
David L. Lopez, Discovery Laboratories, Inc.
Ira L. Kotel, Dickstein Shapiro Morin & Oshinsky LLP

FINANCING AND FUNDING YOUR IN-LICENSING AND CO-DEVELOPMENT DEAL TODAY
Joseph L. Faber, Helix Law Group, P.C.

THE BIOTECHNOLOGY MARKET PLACE
Brian Silver, Morgan Stanley

NEW HOT BUTTONS IN DUE DILIGENCE AND RISK ASSESSMENT
Martin Travers, Sanofi-Synthelabo Inc.

AVOIDING ANTITRUST PITFALLS IN IN-LICENSING, CO-DEVELOPMENT AND CO-PROMOTION
David Balto, White & Case

PRE-DEAL AND STRUCTURE CONSIDERATIONS FOR IN-LICENSING AND CO-DEVELOPMENT AGREEMENTS
Dr. John Gotto, Ph.D., Wyeth Vaccines

PRE-DEAL AND STRUCTURE CONSIDERATIONS
Barclay James Kamb, Cooley Godward LLP

GUILFORD PHARMACEUTICALS ACQUIRES U.S. RIGHTS TO AGGRASTAT® FROM MERCK & CO., INC.
Russell P. Wesdyk, Guilford Pharmaceuticals

SUCCESSFUL IN-LICENSING AND CO-DEVELOPMENT COLLABORATIONS WITH UNIVERSITIES
Susan Galli, Ropes & Gray
Jonathan Lourie, Edwards & Angell, LLP

AVENTIS / GENTA CASE STUDY IN ONCOLOGY LICENSING
Tom Burger, Genta Incorporated
Bruce J. Seeley, Aventis

TERMINATION – WHAT HAPPENS WHEN ONE PARTY WANTS OUT?
Robert Werner, Pfizer, Inc.